IB Ventures, a newly launched Saudi investment platform dedicated to biotechnology, has announced a $50 million venture initiative to accelerate the growth of life sciences startups and attract international biotech companies to the Kingdom.
The platform brings together venture funding, incubation, and acceleration to create an integrated ecosystem that supports both local innovation and global collaboration. Headquartered in Riyadh, IB Ventures is also expanding internationally with offices in Switzerland and the United States, two of the world’s leading biotech hubs.
The firm’s strategy focuses on business development, commercialization, scale-up, and exit planning, backed by an in-house incubator and accelerator. The founding team — Dr. Hamad Al Omar and Dr. Yazeed Al Sufyani — bring deep expertise across biotechnology, venture capital, medical research, and operations.
According to the company, the launch of IB Ventures represents a pivotal step toward building a world-class biotechnology sector in Saudi Arabia, in alignment with Vision 2030’s goal of fostering an innovation-driven economy.
IB Ventures emphasized that its integrated model will help translate early scientific breakthroughs into scalable ventures, bridging the gap between science and enterprise. The company invited investors, partners, and entrepreneurs to collaborate in shaping a new biotech ecosystem that promotes local innovation and global partnerships.
